未经授权:接受经导管主动脉瓣置换术(TAVR)的患者,80-90%是极端的,高,或中间风险。在这些组中考虑徒劳结果的患者选择是困难的,因为显著的合并症负担是常见的。因此,我们根据年龄和合并症检查了TAVR术后1年死亡率.
UNASSIGNED:在2008年至2021年之间,所有丹麦TAVR患者均被纳入。从多元Cox回归模型来看,确定了与1年全因死亡率相关的显著特征.根据基线时存在的显著合并症的数量,将研究人群分为四组:低(0合并症),轻度(1合并症),中度(2种合并症),和高(3个或更多的合并症)。每组估计全因死亡率的1年风险和95%置信区间(CI)。
未经批准:总共,7,104例患者接受TAVR。与1年全因死亡率相关的重要协变量是慢性肾病,心力衰竭,慢性阻塞性肺疾病,外周动脉疾病,年龄≥85岁。四个基线组包括低(n=2,666),轻度(n=2,814),中等(n=1,246),高共病负担(n=378)。在低基线共病负担组中,全因死亡率的1年风险为5.5%(95CI:4.6-6.4%)。相反,高基线负担组的1年全因死亡率风险为25.0%(95CI:20.4~29.3%).
未经评估:在TAVR患者的全国样本中,关于年龄和合并症的现成信息,可用于确定1年死亡率为25%的高危人群。这为医生和患者提供了对TAVR后1年预后的易于理解的观点,并且可以补充患者选择以改善长期结果。
UNASSIGNED: Of patients undergoing transcatheter aortic valve replacement (TAVR), 80-90 % are at extreme, high, or intermediate risk. Patient selection considering futile outcomes in these groups is difficult as significant comorbidity burden is common. Thus, we examined 1-year mortality after TAVR according to age and comorbidities.
UNASSIGNED: Between 2008 and 2021 all Danish TAVR-patients were included. From a multivariate Cox-regression model, significant characteristics associated with 1-year all-cause mortality were identified. The study population was divided into four groups according to number of significant comorbidities present at baseline: Low (0 comorbidities), mild (1 comorbidity), moderate (2 comorbidities), and high (3 or more comorbidities). The 1-year risk of all-cause mortality with 95 % confidence intervals (CI) was estimated by each group.
UNASSIGNED: In total, 7,104 patients underwent TAVR. Significant covariates associated with 1-year all-cause mortality were chronic kidney disease, heart failure, chronic obstructive pulmonary disease, peripheral artery disease, and age ≥ 85 years. The four baseline groups comprised low (n = 2,666), mild (n = 2,814), moderate (n = 1,246), and high comorbidity burden (n = 378). The 1-year risk of all-cause mortality was 5.5 % (95 %CI: 4.6-6.4 %) in the low baseline comorbidity burden group. Conversely, the 1-year risk of all-cause mortality was 25.0 % (95 %CI: 20.4-29.3 %) in the high baseline burden group.
UNASSIGNED: In a national sample of TAVR patients, readily available information on age and comorbidities, can be used to identify a high-risk group with 25 % 1-year mortality. This provides physicians and patients with an easy-to-understand view on 1-year prognosis after TAVR and may complement patient selection for improved long-term outcomes.